First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors

Conclusions DS-8273a was well tolerated and demonstrated linear pharmacokinetics. Decreases in MDSC were temporally associated with DS-8273a exposure. This agent could be studied further in combination with other agents, pending further proof-of-target-engagement.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research